ASPIRE BIOPHARMA HOLDINGS, INC. Business Combination, Acquisition Related Costs
ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP) reported Business Combination, Acquisition Related Costs of $229.42 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2026-08-13
- ASPIRE BIOPHARMA HOLDINGS, INC. business combination, acquisition related costs for the quarter ending 2026-06-30 was $229.42K.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month |
|---|---|---|
| 2026-06-30 | $229.42K 10-Q · filed 2026-08-13 | $229.42K 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |